Complication rates in the clinical practice of long-term use central venous catheters in cancer patients
Keywords:
cancer patients, CRTAbstract
Background. The use of indwelling long term central venous catheters (CVC) has improved the management of cancer patients. However, this device might cause morbidity and lead to a great number of central venous catheter-related thrombosis (CRT). Medical consequences include catheter dysfunction and pulmonary embolism. Vessel injury caused by the procedure of CVC insertion is the most important risk factor for development of CRT. In this retrospective study, we analyzed the incidence and complications of long term use of CVC in adult patients with cancer. Methods. We examined the data about the CVC inserted in our institution during an 8-year period. A single type of port-a-cath was used: BardPort (Bard Access System, Salt Lake City, USA). Two-hundred and ten CVC were placed in 197 consecutive unselected patients; 12 pts received a second device, 1 pt a third one (mean age 63 yrs, range 37-83; Male: Female ratio 123: 74). The follow-up continued until CVC was removed or the patient died. Results. 92 CVC were removed, 79 pts died with CVC in situ; 39 pts are still alive carrying CVC. Over 60978 pt-days of follow-up (mean 310±329, range 1-1752) 37 out of 197 pts (18.8%) showed complications in 37 of 210 CVC (17.6% and 0.61 episodes per 1000 catheter days of use). 12 pts (6%) removed CVC for complications, 2 for sepsis and the other ones for catheter-related thrombosis; 9 pts (4.5%) changed the treatment plan, 1 for sepsis and 8 for CRT. The mean time of CRT was 125±158 days (range 14-746 days). All pts with CRT were treated with anticoagulants, 4 pts underwent thrombolisis treatment, 8 pts needed removal of CVC. 4 port-a-caths reported bacteraemia (1.9% of devices) (0.06 episodes per 1000 catheter days of use). Furthermore only 1 complication (0.5%) life-threatening was reported. Conclusions. We observed that the incidence of CRT is the most frequent complication and it may change the treatment plan in few cases (4%). The efficacy and safety of pharmacologic prophylaxis for CVC related thrombosis is not established and the last recommendations suggest that clinicians do not routinely use prophylaxis to try to prevent thrombosis related to long-term indwelling CVCs in cancer patients. Additional studies performed in high risk populations with appropriate dosage and timing will help to define which patients could benefit from this prophylaxis.
Downloads
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.